News
So Sir Pascal may seem an unlikely ally of Donald Trump, who as America’s president has slashed public spending on scientific ...
NHS England has poured investment into hospitals while neglecting other parts of the service, Lord Ara Darzi concluded last year in his report on a “broken system”. The share of the UK health budget ...
With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as ...
Pascal Soriot's comments came during AstraZeneca's Q2 earnings call in regard to President Donald Trump’s newly announced ...
AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...
Today’s Forbes CFO newsletter focuses on Aradhana Sarin’s journey from treating patients to becoming what she calls a ...
We will be totally self-sufficient for the supply of medicines to American patients.” AstraZeneca CEO Pascal Soriot on the company’s plan to invest $50 billion in the U.S.
AstraZeneca’s CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing ...
AstraZeneca has proposed price cuts to its drugs in the United States, its CEO said on Tuesday, days after unveiling a $50 ...
In an earnings call on July 29th, in which the company reported a 13% increase in half-year profits, he said about Britain ...
Speaking from Astra's offices in New York, Sir Pascal Soriot (pictured) said it was 'global', but it was 'very much rooted ...
One of Trump's demands was that the CEOs' companies limit drug costs for states' Medicaid plans to "most-favored nation" ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results